Comparison of Secukinumab and Ixekizumab in psoriasis: a real-life cohort study on the efficacy and drug survival of 445 patients

J Eur Acad Dermatol Venereol. 2022 Mar;36(3):e233-e235. doi: 10.1111/jdv.17766. Epub 2021 Nov 7.

Authors

C Cariti¹, P Dapavo¹, L Mastorino¹, M Ortoncelli¹, N Siliquini¹, M Merli¹, G Avallone¹, S Giordano¹, R Fabrizio¹, S Susca¹, A Verrone¹, E Stroppiana¹, P Quaglino¹, S Ribero¹

Affiliation

¹ Department of Medical Sciences, Section of Dermatology, University of Turin, C.so Dogliotti, Turin, 14 - 10126, Italy.

PMID: 34672026
DOI: 10.1111/jdv.17766

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Cohort Studies
Humans
Pharmaceutical Preparations*
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Pharmaceutical Preparations
ixekizumab
secukinumab